USFDA issues Form 483 with 8 observations to Aurobindo’s Telangana unit
Aurobindo Pharma on Friday said the US health regulator has issued a Form 483 with eight observations after inspecting its Telangana-based manufacturing plant. The US Food and Drug Administration (US FDA) inspected the company’s Unit-XII, which includes both oral solids and injectable manufacturing units, situated at Bachupally, Telangana from August 25 to September 5, the…